Eli Lilly: The Hundred-and-Fifty-Year-Old Disruptor

In 1876, a thirty-eight-year-old pharmaceutical chemist and Union Army veteran named Eli Lilly, who carried the rank of colonel from the Civil War, opened a small laboratory in Indianapolis with a sign over the door reading, simply, “Eli Lilly, Chemist.”

His ambition was modest in scale but radical in principle. The patent medicines of the era were largely fraudulent, unreliable concoctions of dubious ingredients and wild claims. Lilly’s idea was to make medicines that actually worked, manufactured to a high and consistent standard, and dispensed only on a physician’s prescription rather than hawked as cure-alls. One of his first products was quinine, to treat malaria. By the end of that first year, the company had made a few thousand dollars in sales. It was the seed of something that would still be standing, and leading, a hundred and fifty years later, because the founding principle, that a medicine company should be built on rigorous science and quality rather than salesmanship, became the company’s enduring DNA.

The Century of Breakthroughs

What makes Eli Lilly extraordinary is not any single drug but the sheer span of its consequential ones, each defining an era of medicine.

The first and most world-changing came in 1923. When researchers in Toronto discovered insulin, the treatment that turned diabetes from a death sentence into a manageable condition, it was Eli Lilly that solved the staggering problem of manufacturing it at scale, becoming the first company to mass-produce commercial insulin, under the name Iletin, and putting a life-saving medicine into the hands of millions. It was, in a sense, the original version of the very thing Lilly would become famous for again a century later: mastering the industrial production of a metabolic medicine the world desperately needed.

The breakthroughs kept coming, decade after decade, in a way few companies have ever matched. In the 1950s, Lilly was a major manufacturer of the Salk polio vaccine, helping to defeat one of the great scourges of childhood. In 1982 it launched Humulin, the first human insulin produced through recombinant DNA technology, a landmark of the new age of biotechnology. And in 1987 it launched Prozac, the first of the SSRI antidepressants, a drug that did not merely sell in the billions but genuinely reshaped how the world understood and treated depression, entering the culture as few medicines ever have. Insulin, the polio vaccine, Prozac: a single company stood behind three of the most consequential pharmaceutical achievements of the twentieth century.

The Cliff, and the Discipline That Answered It

But greatness across eras is not the same as smooth sailing, and in the early 2010s Eli Lilly faced the crisis that periodically threatens every pharmaceutical company: the patent cliff. A drug’s patent protection lasts only so long; when it expires, cheap generic copies flood in and the revenue from what was once a blockbuster can collapse almost overnight. In the early 2010s, several of Lilly’s biggest drugs lost their exclusivity in a cluster, and the company faced years of declining or stagnant revenue, a genuinely dangerous stretch that tempts a management team toward defensive financial maneuvers, cost-cutting, and the abandonment of expensive long-term research.

The Drug That Made a Trillion

The instrument of Lilly’s ascent was a molecule called tirzepatide, and to understand why it mattered you have to recall the rival. By the early 2020s, the Danish company Novo Nordisk had ignited a revolution with its GLP-1 drugs, Ozempic for diabetes and Wegovy for obesity, which produced unprecedented weight loss and became global phenomena. Novo was first, dominant, and seemingly unassailable.

But Lilly had been working in the same scientific territory, and its molecule was different in a crucial way. Where Novo’s semaglutide acted on a single gut hormone, Lilly’s tirzepatide acted on two at once, a dual mechanism that, in practice, produced even greater weight loss. Launched as Mounjaro for diabetes in 2022 and as Zepbound for obesity in 2023, tirzepatide did to the dominant incumbent what the framework teaches us to watch for: it did not merely match the leader, it beat it on the thing that mattered most, efficacy. In a head-to-head trial, patients lost more weight on Lilly’s drug than on Novo’s. Prescriptions began shifting. And the financial consequence was staggering: by 2024, the two tirzepatide brands together were generating over sixteen billion dollars a year, accounting for more than a third of Lilly’s revenue, and growing explosively. The stock soared, and in November of 2025, Eli Lilly became the first healthcare company in history to be worth a trillion dollars.

It is worth being precise about the moat, because it is layered and instructive. There is the intellectual property, the patents on tirzepatide. There is the colossal, hard-won manufacturing capability, the same kind of industrial mastery Lilly first demonstrated with insulin a century earlier, now turned to producing complex peptide drugs at a scale the exploding demand required, a capability that takes years and billions to build and that protects the franchise from fast followers. And there is the deep, institutional expertise in metabolic science accumulated over a hundred years. Crucially, Lilly did not bet only on tirzepatide: even as the obesity franchise exploded, it kept the wide research base that had carried it across previous eras, advancing a new Alzheimer’s treatment, building in oncology and immunology, pushing toward oral and next-generation metabolic drugs, and launching a direct-to-consumer service to sell its medicines more directly. The refusal to let one miraculous product consume its broader scientific ambition is the behavior of a company that has lived through enough patent cliffs to know that today’s miracle is tomorrow’s generic.

The Decision a Soaring Winner Faces

What Everyone Got Wrong

Eli Lilly has been underestimated in ways worth naming.

Mistake #1: “The first mover in weight-loss drugs will win.” Reality: Novo Nordisk was first and dominant; Lilly came second with a better molecule and took the larger prize.

Mistake #2: “A patent cliff is the beginning of the end.” Reality: Lilly answered its early-2010s cliff with heavy R&D and emerged with the franchise that made it worth a trillion.

Mistake #3: “A 150-year-old company is past its prime.” Reality: In its 146th year Lilly launched the drug that made it the most valuable healthcare company in history.

Mistake #4: “Becoming the biggest winner removes the risk.” Reality: A valuation priced for perfection can swing violently on a single rival trial or pricing headline.

The Honest Present

The framework demands honesty about the present, and the present is a company at a euphoric peak, with all the strength and all the risk that implies. Eli Lilly in 2026 is one of the most valuable companies in the world, the leader of the most exciting and lucrative new market in medicine, riding extraordinary growth, armed with the best-selling drug in its class and a deep pipeline, backed by a hundred and fifty years of proven reinvention. These are immense strengths.

But its valuation is extraordinarily high, pricing in years of continued dominance and leaving little room for disappointment; it faces a wounded but determined Novo Nordisk and a field of rivals racing to develop superior drugs; it is exposed to the intense political and public pressure over the price of its weight-loss drugs; and like every pharmaceutical company, it lives in the permanent shadow of its own future patent cliffs and the possibility that a competitor will someday do to tirzepatide exactly what tirzepatide did to semaglutide. The bull case is that Lilly has only begun to exploit a vast, decade-long obesity-treatment boom and has the science and scale to lead it; the bear case is that the valuation is priced for perfection in a fiercely competitive field where the lead can change hands on a single trial. The hundred-and-fifty-year-old disruptor sits, for now, on top of the world.

Why This Matters to Investors

Eli Lilly offers an investor several durable lessons. The first is that being best beats being first: Lilly did not invent the weight-loss revolution but won it with a superior drug, a reminder that first-mover advantage is weaker than commonly believed. The second is that the most important capital decisions are made in the hard years: Lilly’s choice to answer a patent cliff with research rather than retreat is what produced its trillion-dollar franchise. And the third is the discipline of reinvention: a company that refuses to be defined by past success, moving from insulin to Prozac to incretins, can stay great across a century and a half. Studying Lilly trains an investor to question first-mover hype, to watch how companies behave under adversity, and to prize durable reinvention. None of this is investment advice.

Lessons in Order of Depth

On the surface: the Method

Being first is overrated; being better is what wins. Eli Lilly did not invent the GLP-1 weight-loss revolution, Novo Nordisk did, and Novo was years ahead, dominant, and seemingly entrenched. Lilly won anyway, by developing a drug that simply worked better. First-mover advantage is far weaker than it is commonly assumed to be, markets defined by performance reward the best product more than the earliest one, and a patient, well-resourced second mover who out-engineers the pioneer can capture the prize the pioneer created, so the right question is rarely “can we be first” but “can we be best.”

Below the surface: the Money

Lilly’s trillion-dollar triumph was set up by a decision made in adversity, a decade earlier, to answer a patent cliff with reinvestment rather than retreat. When its old blockbusters were dying and the temptation was to cut costs and engineer the financials, Lilly instead kept pouring money into research, and that refusal to starve the future to protect the present is what produced tirzepatide. The most important capital-allocation decisions are often made in the hard years, a company’s willingness to keep investing in its long-term capability through a downturn is a powerful signal of quality, and the seeds of the greatest triumphs are frequently planted in the response to the worst crises.

Below that: the Mind

Eli Lilly embodies the psychological discipline of reinvention, the refusal to be defined or limited by past success. A company that gave the world insulin, the polio vaccine, and Prozac could easily have rested on a glorious history, become a museum of its own past achievements, and slowly declined, as so many once-great companies do. Instead, again and again across a hundred and fifty years, it reinvented what it was, moving from insulin to antidepressants to incretins, each time mastering a new science rather than clinging to the old. Durable greatness requires a kind of restless humility, a willingness to let go of the identity that made you successful in one era in order to become what the next era demands, and the deadliest trap for an individual or an institution is to mistake past achievement for permanent identity.

At the deepest level: the question it leaves us

Eli Lilly, read beside Novo Nordisk, forces us to confront an uncomfortable truth about pioneers and the fruits of their labor. Novo Nordisk made the lonely, century-long, scientifically heroic bet that created the obesity-drug revolution; it took the deepest risk and did the foundational work. And then Eli Lilly, coming second, built a better version and took the larger prize. This is one of the oldest and most unsettling patterns in the history of innovation: that the pioneer who bears the risk and opens the frontier is so often not the one who reaps the greatest reward, that the fast, well-armed follower who improves on the breakthrough frequently wins the war the pioneer began. The deepest question Lilly leaves us is whether this is a tragedy or a kind of justice, whether we should mourn that the boldest innovator is not always the biggest winner, or accept that what ultimately serves the world is not who was first but who does it best; and whether, in our own lives, the lesson is to race to be the pioneer, with all its risk and glory and frequent disappointment, or to cultivate the patient discipline of the one who watches, learns, improves, and wins.

The Legendary Scorecard

Eight fixed categories, each scored out of ten. The overall is an editorial verdict, a judgment, and explicitly not a weighted average.

Category	Score	Note
Founder Vision	8	Colonel Lilly’s principle of rigorous, prescription-based medicine endured 150 years
Innovation	9	Insulin, the polio vaccine, Prozac, and tirzepatide across a century and a half
Execution	9	Out-executed a dominant first mover and scaled manufacturing brilliantly
Moat	8	Patents, vast peptide manufacturing, and deep metabolic-science expertise
Capital Allocation	8	Answered a patent cliff with R&D reinvestment, setting up the metabolic franchise
Wealth Creation	9	Became the first healthcare company worth $1 trillion
Durability	9	150 years of reinvention across multiple eras of medicine
Historical Importance	9	Behind three of the most consequential drugs of the modern era
Overall Legendary	8.5	Editorial verdict: a 150-year-old disruptor that out-innovated the pioneer, at a richly-priced peak

At a Glance

The Eli Lilly Timeline

• 1876: Colonel Eli Lilly founds the company in Indianapolis.
• 1881: The company is formally incorporated.
• 1923: Lilly becomes the first company to mass-produce commercial insulin (Iletin).
• 1955: It plays a major role in mass-producing the Salk polio vaccine.
• 1982: It launches Humulin, the first human insulin made via recombinant DNA.
• 1987: Prozac launches as the first SSRI antidepressant and a blockbuster.
• Early 2010s: Lilly weathers a patent cliff as key drugs lose exclusivity.
• 2022: Tirzepatide launches as Mounjaro for diabetes.
• 2023: Tirzepatide is approved for obesity as Zepbound.
• 2024-2025: Tirzepatide outsells and outperforms rivals, driving explosive growth.
• 2025: In November, Lilly becomes the first healthcare company worth $1 trillion.
• 2026: Lilly is among the most valuable companies on Earth, valued near $1 trillion.

Key Numbers

Related Reading

Eli Lilly is best read immediately beside Novo Nordisk, the pioneer it out-innovated, the two chapters forming a single lesson about who creates a market and who wins it. Read it with Berkshire Hathaway, whose lesson on the discipline of capital allocation illuminates Lilly’s decision to answer a patent cliff with research rather than retreat, and with ASML, another science-and-IP-driven leader whose hard-won manufacturing depth mirrors the moat Lilly built. For the underlying principle, visit our hub on patent and manufacturing moats and the overrated power of first-mover advantage.

Go Deeper

The Complete Trader’s Edge book builds the full Mind, Method, and Money framework that turns stories like this into a repeatable way of reading any company. Eli Lilly teaches you that being best beats being first and that the hard years set up the great triumphs; the book teaches you the discipline to act on both.

This article is part of the Greatest Companies series, adapted from the book Greatest Companies, now available on Kindle.

Frequently Asked Questions

When was Eli Lilly founded, and by whom?

Eli Lilly and Company was founded in May 1876 in Indianapolis, Indiana, by Colonel Eli Lilly, a pharmaceutical chemist and Union Army veteran of the Civil War. His founding principle was to make high-quality medicines that actually worked, dispensed by prescription, in contrast to the fraudulent patent medicines common at the time.

What are Mounjaro and Zepbound?

Both are brand names for tirzepatide, Eli Lilly’s blockbuster metabolic drug: Mounjaro is approved for type 2 diabetes (2022) and Zepbound for obesity (2023). Tirzepatide acts on two gut hormones at once, a dual mechanism that produced greater weight loss than Novo Nordisk’s single-hormone semaglutide in head-to-head trials, and it became the engine of Lilly’s explosive growth.

How did Eli Lilly become the first trillion-dollar healthcare company?

Through the explosive success of tirzepatide. By 2024 the Mounjaro and Zepbound brands together generated over $16 billion a year, more than a third of Lilly’s revenue, and growing fast. The market rewarded that growth, and in November 2025 Eli Lilly became the first healthcare company in history to reach a $1 trillion market value.

How is Eli Lilly different from Novo Nordisk?

Novo Nordisk pioneered the GLP-1 weight-loss revolution with Ozempic and Wegovy and was first and dominant. Eli Lilly came second, but its drug tirzepatide acted on two hormones rather than one and produced greater weight loss, allowing it to take market share and ultimately surpass Novo in value. The two illustrate a classic pattern: the pioneer opens the market, but the better product can win it.

What are the main risks facing Eli Lilly in 2026?

Chiefly its very high valuation, which prices in years of continued dominance and leaves little room for disappointment. It also faces a determined Novo Nordisk and other rivals racing to develop superior drugs, intense political pressure over the price of weight-loss drugs, and the permanent pharmaceutical reality of future patent cliffs, the possibility that a competitor will someday do to tirzepatide what tirzepatide did to semaglutide. None of this is investment advice.